Order results by:
Issue | Title | |
Vol 15, No 4 (2022) | Possibilities of physical therapy and electrophysical modalities in the complex therapy of pneumonia | Abstract similar documents |
D. I. Korabelnikov, V. V. Grigoryev, О. V. Efimova | ||
"... .), but also include non-material costs from pneumonia, which include pain, psycho-emotional experiences ..." | ||
Vol 11, No 4 (2018) | Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis | Abstract similar documents |
I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina | ||
"... for the evaluation of pharmacotherapy costs in pediatric inpatients diagnosed with community-acquired pneumonia ..." | ||
Vol 11, No 3 (2018) | Use of medications in children hospitalized with community-acquired pneumonia | Abstract similar documents |
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova | ||
"... pneumonia. Materials and methods. Medical records of 547 children treated for community-acquired pneumonia ..." | ||
Vol 16, No 3 (2023) | Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia | Abstract similar documents |
A. A. Taube, T. V. Alexandrova, O. A. Demidova, M. V. Zhuravleva | ||
"... Background. The global recommendations for the treatment strategy of community-acquired pneumonia ..." | ||
Vol 9, No 2 (2016) | EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL | Abstract similar documents |
I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova | ||
"... pneumonia. Materials and methods. It was selected 30 medical histories of patients with severe community ..." | ||
Vol 11, No 1 (2018) | Antimicrobial therapy of community-acquired pneumonia in a hospital setting (clinical and economic aspects) | Abstract similar documents |
O. V. Zhukova, O. V. Ruina, M. V. Khazov, S. V. Romanov | ||
"... ) of community-acquired pneumonia (CAP) in a hospital ptactice. Materials and methods. Case reports of 48 ..." | ||
Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract similar documents |
V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
"... for the treatment of community-acquired pneumonia (CAP) in outpatient conditions. Materials and methods. 650 ..." | ||
Vol 18, No 2 (2025) | Clinical and economic evaluation of antibacterial therapy for nosocomial pneumonia on the example of a multidisciplinary hospital in Moscow | Abstract similar documents |
D. D. Ivanova, I. N. Sychev, N. B. Lazareva | ||
"... . Conclusion. Antibacterial therapy costs for nosocomial pneumonia significantly increase the total cost ..." | ||
Vol 7, No 1 (2014) | CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT | Abstract similar documents |
I. I. Shteynberg, S. K. Zyryanov, Yu. B. Belousov | ||
"... efficacy of carbapenems in nosocomial pneumonia treatment. The study included 87 patients divided into 3 ..." | ||
Vol 16, No 1 (2023) | Non-invasive respiratory support in patients with severe community-acquired pneumonia | Abstract similar documents |
S. V. Korotchenko, D. I. Korabelnikov | ||
"... early use of intubation and artificial lung ventilation (ALV) in patients with severe pneumonia ..." | ||
Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
"... analysis of long-term consequences involved calculating the cost of pharmacotherapy and the costs ..." | ||
Vol 16, No 4 (2023) | Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: modeling results | Abstract similar documents |
V. I. Ignatyeva, D. Yu. Ovsyannikov, A. E. Tsygankov, E. E. Yagnenkova, V. R. Amirova, M. M. Maryanyan, A. S. Mokrova | ||
"... infections (LRTI), including acute bronchiolitis and pneumonia, in children in the first 5 years of life ..." | ||
Vol 5, No 2 (2012) | THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS | Abstract similar documents |
A. I. Ovod, M. D. Mukovnina | ||
"... лечение беременных женщин, больных сифилисом, а также членов их семей осуществляется за счет ..." | ||
Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
Anton Alexandrovich Kasatkin | ||
"... of analysis of the cost of the disease, including the payment of medical costs for medical services, medicines ..." | ||
Vol 5, No 2 (2012) | METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES | Abstract similar documents |
R. I. Yagudina, I. V. Sorokovikov | ||
"... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..." | ||
Vol 7, No 1 (2014) | ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT | Abstract similar documents |
M. A. Shapovalova, L. R. Koretskaya | ||
"... of pharmacotherapy and medical services in the department of neurology. An assessment of the costs of hospitalization ..." | ||
Vol 9, No 4 (2016) | THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE | Abstract similar documents |
G. E. Ulrikh, A. V. Rudakova | ||
"... levo isomer ropivacaine. The aim of this work was to assess the cost of anesthesia levobupivacaine ..." | ||
Vol 12, No 1 (2019) | Individual cost accounting in the management of medical organizations | Abstract similar documents |
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali | ||
"... In the modern economic conditions, the rational planning of costs and the complex process ..." | ||
Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
"... -to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe ..." | ||
Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
R. I. Yagudina, M. M. Murashko | ||
"... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..." | ||
Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
"... direct healthcare costs and incremental cost-effectiveness ratios (ICERs) per 1 life year gained were ..." | ||
Vol 5, No 1 (2012) | COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS | Abstract similar documents |
R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko | ||
"... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..." | ||
Vol 12, No 3 (2019) | Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” | Abstract similar documents |
S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva | ||
"... Objective: to analyze whether comorbidity affects the cost of treatment and medical services ..." | ||
Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
"... on the analysis of its cost and effectiveness in patients with chronic pain syndrome in pancreatic cancer ..." | ||
Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
"... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..." | ||
Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
M. B. Kubaeva, Y. Sh. Guchshina | ||
"... The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use ..." | ||
Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
"... of this study is to compare costs associated with these options in Russia. Materials and methods. We calculated ..." | ||
Vol 15, No 2 (2022) | Pharmacoeconomic study of the treatment of arterial hypertension in children and adolescents using cost-of-illness analysis | Abstract similar documents |
O. S. Mikhaylova, A. V. Krikova | ||
"... Background. The cost-of-illness (COI) analysis allows to estimate and plan costs for calculations ..." | ||
Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract similar documents |
R. Yagudina, A. Kulikov, B. Misikova | ||
"... Цель исследования: Провести фармакоэкономический анализ лечения второй и третьей линий ..." | ||
Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
R. I. Yagudina, V. G. Serpik | ||
"... out by mean of «cost-efficacy» analysis, as the main performance indicator has been selected ..." | ||
Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
"... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..." | ||
Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS | Abstract similar documents |
M. V. Protsenko | ||
"... of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost ..." | ||
Vol 11, No 4 (2018) | Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach | Abstract similar documents |
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya | ||
"... special attention to the model type, the modeling methodology, information on the effectiveness and cost ..." | ||
Vol 10, No 2 (2017) | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA | Abstract similar documents |
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov | ||
"... . Retrospective comparative pharmacoeconomic study; cost-minimization analysis and budget-impact analysis ..." | ||
Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
"... . The cost-effectiveness ratios for omalizumab, mepolizumab and reslizumab were calculated and compared ..." | ||
Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
"... (medical, social etc.) throughout their life and the cost of the care has never been calculated in Russia ..." | ||
Vol 12, No 4 (2019) | Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis | Abstract similar documents |
I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva | ||
"... & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment ..." | ||
Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
S. K. Zyryanov, I. N. Dyakov | ||
"... in terms of overall survival and progression-free survival. Therefore, a cost minimization analysis method ..." | ||
Vol 13, No 4 (2020) | Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy | Abstract similar documents |
I. N. Dyakov, S. R. Varfolomeеva | ||
"... data. The methods of pharmacoeconomic analysis included a clinical-economic analysis (cost ..." | ||
Vol 6, No 2 (2013) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS | Abstract similar documents |
A. Yu. Kulikov, V. G. Serpik | ||
"... with Dorzopt and Trusopt from cost-efficacy perspective and can be claimed dominant. Futhermore Azopt ..." | ||
Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
"... ’ medical records. The cost-effectiveness analysis, incremental analysis, and «budget impact» analysis were ..." | ||
Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
A. U. Kulikov | ||
"... химиотерапии 1-й линии проводят 2-ю линию лечения НМРЛ. В качестве препаратов 2-й линии монотерапии НМРЛ ..." | ||
Vol 11, No 2 (2018) | Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer | Abstract similar documents |
G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin | ||
"... the treatment costs in patients with breast cancer while maintaining a high treatment efficacy and quality ..." | ||
Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
A. Yu. Kulikov, I. V. Novikov | ||
"... The analysis goal is to determine the cost-effectiveness of liraglutideas add-on to metformin ..." | ||
Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
"... . The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost ..." | ||
Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
"... performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..." | ||
Vol 10, No 4 (2017) | THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE | Abstract similar documents |
Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva | ||
"... this standard provides an opportunity for calculating the costs of implementing the SGP, the past experience ..." | ||
Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
"... Objective: to perform cost-effectiveness analysis of brentuximab vedotin (BV) in patients ..." | ||
Vol 8, No 2 (2015) | CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA | Abstract similar documents |
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova | ||
"... . For the pharmacoeconomic analysis we used the cost-effectiveness ratio. Results. Our analysis showed that the scheme ..." | ||
Vol 10, No 3 (2017) | Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients | Abstract similar documents |
N. K. Mazina, P. V. Mazin | ||
"... (after treatment with docetaxel) in the Russian Federation. Materials and Methods. A cost effectiveness ..." | ||
1 - 50 of 311 Items | 1 2 3 4 5 6 7 > >> |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)